Clinical Trial Update: SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Cobomarsen (MRG-106) versus an active comparator in Mycosis Fungoides, a form of Cutaneous T-Cell Lymphoma; study terminated with poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides

Drugs mentioned

• Cobomarsen (MRG-106)

Snippet

Sponsor: miRagen Therapeutics, Inc. | Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Phase 2 | Status: TERMINATED | Results posted: 2022-04-08